Stoke Therapeutics, Inc. (STOK)
After hours:
| Previous close | 13.90 |
| Open | 13.99 |
| Bid | 14.46 x 100 |
| Ask | 14.60 x 200 |
| Day's range | 13.66 - 14.65 |
| 52-week range | 3.35 - 17.58 |
| Volume | |
| Avg. volume | 610,977 |
| Market cap | 766.025M |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.17 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.50 |
Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass., August 16, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that, effective on August 15, 2024, the company granted stock options to purchase an aggregate of 48,400 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Simply Wall St.Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Stoke Therapeutics ( NASDAQ:STOK ) Second Quarter 2024 Results Key Financial Results Net loss: US$25.7m (loss narrowed...
ZacksStoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 19.30% and 45.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
